MBOT’s main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for ...

Harel Gadot, CEO of Microbot Medical Inc. (NASDAQ:MBOT), was recently a guest on Benzinga's All Access. Microbot Medical makes the LIBERTY® Endovascular Robotic System, a single-use, fully disposable ...

HINGHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, announced its participation in the inaugural ...

HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from ...

Microbot Medical Inc. MBOT recently received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a major regulatory milestone for the company. The LIBERTY system is designed to ...

The Company’s Initial Addressable Market Includes Approximately 2.5 Million Peripheral Endovascular Procedures in the U.S. Annually CEO, President & Chairman to Present Live Webcast at the H.C.

Microbot Medical has secured a non-dilutive NIS2.15m (around $630,000) grant from the Israel Innovation Authority (IIA) to bolster its manufacturing capabilities, as well as progress towards the ...

Microbot Medical has received the FDA’s blessing for its miniature, remote-controlled robot for endovascular procedures, designed to offer clinicians the freedom to sit comfortably and operate outside ...

Medical device manufacturers, investors, healthcare providers, and patients see surgical robotics as one of medicine’s new frontiers --- one which promises to open access, streamline workflows and ...